We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Multi-Pathogen Test Screens for In-Hospital Sepsis

By Labmedica staff writers
Posted on 05 Aug 2008
A new, fast-acting diagnostic technique has been launched to simultaneously verify a complex range of targets that indicate sepsis, the leading cause of death in non-coronary intensive care units worldwide.

Diagnosis of sepsis needs to be made during the first days of the disease. More...
Currently, physicians and clinicians choose among several tests with little confidence that the results will identify whether a patient is suffering from sepsis. Alternatively, they can order a multiple-phase blood culture test covering a range of specific targets. This is an expensive process requiring time for a disease that causes rapid deterioration in the patient's condition.

The new diagnostic technique was developed by Seegene (Seoul, Korea) and it is called the Seeplex sepsis multi-pathogen screening test. The test simultaneously screens for 64 sepsis-causing pathogens: 48 Gram-positive bacteria, 10 Gram-negative bacteria, and 6 fungi. Additionally, four drug-resistant genes: vancomycin resistant vanA and vanB; methicillin-resistant mecA; and blaSHV, a plasmid borne gene for Klebsiella pneumoniae, can be discriminated. The Seeplex Sepsis test requires only 0.4 ml of a patient's whole blood and provides test results in five hours.

The Seeplex system is a multiplexing polymerase chain reaction (PCR) technology that enables simultaneous multi-pathogen detection. Seegene applies its Seeplex system utilizing dual priming oligo (DPO) technology to create multi-pathogen tests delivering maximum specificity, reproducibility, and sensitivity. Seeplex can be applied to a broad range of molecular diagnostics.

In a recent clinical study in Korea, the Seeplex testing approach demonstrated higher sensitivity than the blood culture test-methodology. Out of 370 hospital patients suspected of having sepsis, 53 patients tested positive using the Seeplex Sepsis test while 32 patients tested positive using the blood culture method. In addition, the Seeplex test identified those higher rates of infection on the same day that blood samples were taken whereas blood cultures took three to four days.

"The Seeplex Sepsis DNA test is a fundamental breakthrough for accurate, rapid, and cost-effective sepsis diagnostics,” said Jong-Yoon Chun, CEO of Seegene. "We believe the Seeplex testing system opens a new window for not only saving lives but also furthering understanding of this complex disease by providing precise information of infected pathogens at the earliest possible stage.”


Related Links:
Seegene

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.